TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

Vertex Pharmaceuticals

VRTX
RespiratoryMetabolicNeurology
Biotech

Vertex Pharmaceuticals is a biotechnology company focused on Respiratory, Metabolic, Neurology. Key products include JOURNAVX.

$10.3B
Revenue (2024)
$120.0B
Market Cap
-
Trials
19
Approved (2yr)

Key Drugs

JOURNAVX
suzetrigine
Pain
NaV1.8 2 indications · 2025
KALYDECO
ivacaftor
Respiratory
CFTR 1 indications · 2012
ORKAMBI
ivacaftor
Respiratory
CFTR 1 indications · 2015
SYMDEKO (COPACKAGED)
ivacaftor
Respiratory
CFTR 1 indications · 2018
ALYFTREK
deutivacaftor
Respiratory
CFTR 1 indications · 2024

Recent Activity

JOURNAVX 2026-01-23
Labeling
KALYDECO 2025-09-25
Labeling
KALYDECO 2025-09-25
Labeling
ORKAMBI 2025-09-25
Labeling
SYMDEKO (COPACKAGED) 2025-09-25
Labeling
TRIKAFTA (COPACKAGED) 2025-09-25
Labeling
ALYFTREK 2025-09-25
Labeling
ORKAMBI 2025-09-25
Labeling
TRIKAFTA (COPACKAGED) 2025-09-25
Labeling
KALYDECO 2025-05-22
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 95%
4 drugs Phase 3: 50 Phase 2: 10 Phase 1: 18
Metabolic 3%
0 drugs Phase 3: 2 Phase 1: 1
Neurology 1%
0 drugs Phase 2: 2
Immunology 1%
0 drugs Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

GSK big-pharma
Respiratory, Immunology, Neurology
Sanofi big-pharma
Metabolic, Immunology, Respiratory
Eli Lilly big-pharma
Metabolic, Immunology, Neurology
Roche big-pharma
Neurology, Immunology, Respiratory
AstraZeneca big-pharma
Respiratory, Metabolic, Immunology